These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35595822)

  • 1. SHR1032, a novel STING agonist, stimulates anti-tumor immunity and directly induces AML apoptosis.
    Song C; Liu D; Liu S; Li D; Horecny I; Zhang X; Li P; Chen L; Miller M; Chowdhury R; Issa M; Shen R; Yan Y; Zhang F; Zhang L; Zhang L; Bai C; Feng J; Zhuang L; Zhang R; Li J; Wilkinson H; Liu J; Tao W
    Sci Rep; 2022 May; 12(1):8579. PubMed ID: 35595822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors.
    Francica BJ; Ghasemzadeh A; Desbien AL; Theodros D; Sivick KE; Reiner GL; Hix Glickman L; Marciscano AE; Sharabi AB; Leong ML; McWhirter SM; Dubensky TW; Pardoll DM; Drake CG
    Cancer Immunol Res; 2018 Apr; 6(4):422-433. PubMed ID: 29472271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The stimulator of interferon genes (STING) agonists for treating acute myeloid leukemia (AML): current knowledge and future outlook.
    Song X; Peng Y; Wang X; Chen Q; Lan X; Shi F
    Clin Transl Oncol; 2023 Jun; 25(6):1545-1553. PubMed ID: 36587109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of STING inhibits cervical cancer tumor growth through enhancing the anti-tumor immune response.
    Shi F; Su J; Wang J; Liu Z; Wang T
    Mol Cell Biochem; 2021 Feb; 476(2):1015-1024. PubMed ID: 33141310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and Mechanistic Study of a Novel Human-Stimulator-of-Interferon-Genes Agonist.
    Zhang X; Liu B; Tang L; Su Q; Hwang N; Sehgal M; Cheng J; Ma J; Zhang X; Tan Y; Zhou Y; Duan Z; DeFilippis VR; Viswanathan U; Kulp J; Du Y; Guo JT; Chang J
    ACS Infect Dis; 2019 Jul; 5(7):1139-1149. PubMed ID: 31060350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amplifying STING activation by bioinspired nanomedicine for targeted chemo- and immunotherapy of acute myeloid leukemia.
    Wang X; Huang R; Wu W; Xiong J; Wen Q; Zeng Y; Chen T; Li J; Zhang C; Zhong JF; Yang S; Zhang X
    Acta Biomater; 2023 Feb; 157():381-394. PubMed ID: 36375786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.
    Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K
    J Hematol Oncol; 2022 Oct; 15(1):142. PubMed ID: 36209176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STAT3 inhibition enhances CDN-induced STING signaling and antitumor immunity.
    Pei J; Zhang Y; Luo Q; Zheng W; Li W; Zeng X; Li Q; Quan J
    Cancer Lett; 2019 May; 450():110-122. PubMed ID: 30790684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors.
    Perera SA; Kopinja JE; Ma Y; Muise ES; Laskey J; Chakravarthy K; Chen Y; Cui L; Presland J; Sathe M; Javaid S; Minnihan EC; Ferguson HM; Piesvaux J; Pan BS; Zhao S; Sharma SK; Woo HC; Pucci V; Knemeyer I; Cemerski S; Cumming J; Trotter BW; Tse A; Khilnani A; Ranganath S; Long BJ; Bennett DJ; Addona GH
    Mol Cancer Ther; 2022 Feb; 21(2):282-293. PubMed ID: 34815361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of Interleukin-15 With a STING Agonist, ADU-S100 Analog: A Potential Immunotherapy for Prostate Cancer.
    Esteves AM; Papaevangelou E; Dasgupta P; Galustian C
    Front Oncol; 2021; 11():621550. PubMed ID: 33777767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyto-IL-15 synergizes with the STING agonist ADU-S100 to eliminate prostate tumors and confer durable immunity in mouse models.
    Papaevangelou E; Esteves AM; Dasgupta P; Galustian C
    Front Immunol; 2023; 14():1196829. PubMed ID: 37465665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacillus Calmette-Guérin Overexpressing an Endogenous Stimulator of Interferon Genes Agonist Provides Enhanced Protection Against Pulmonary Tuberculosis.
    Dey RJ; Dey B; Singh AK; Praharaj M; Bishai W
    J Infect Dis; 2020 Mar; 221(7):1048-1056. PubMed ID: 30901058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonism of regulatory ISGs enhances the anti-melanoma efficacy of STING agonists.
    Filderman JN; Taylor JL; Wang J; Zhang Y; Singh P; Ross MA; Watkins SC; Nedal Al Bzour A; Karapetyan L; Kalinski P; Storkus WJ
    Front Immunol; 2024; 15():1334769. PubMed ID: 38312842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice.
    Foote JB; Kok M; Leatherman JM; Armstrong TD; Marcinkowski BC; Ojalvo LS; Kanne DB; Jaffee EM; Dubensky TW; Emens LA
    Cancer Immunol Res; 2017 Jun; 5(6):468-479. PubMed ID: 28483787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.
    Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Non-Nucleotide Small-Molecule STING Agonists
    Cherney EC; Zhang L; Lo J; Huynh T; Wei D; Ahuja V; Quesnelle C; Schieven GL; Futran A; Locke GA; Lin Z; Monereau L; Chaudhry C; Blum J; Li S; Fereshteh M; Li-Wang B; Gangwar S; Pan C; Chong C; Zhu X; Posy SL; Sack JS; Zhang P; Ruzanov M; Harner M; Akhtar F; Schroeder GM; Vite G; Fink B
    J Med Chem; 2022 Feb; 65(4):3518-3538. PubMed ID: 35108011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
    Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT
    Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking Tim-3 enhances the anti-tumor immunity of STING agonist ADU-S100 by unleashing CD4
    Luo J; Pang S; Hui Z; Zhao H; Xu S; Yu W; Yang L; Sun Q; Hao X; Wei F; Wang J; Ren X
    Theranostics; 2023; 13(14):4836-4857. PubMed ID: 37771774
    [No Abstract]   [Full Text] [Related]  

  • 19. STING-activating cyclic dinucleotide-manganese nanoparticles evoke robust immunity against acute myeloid leukemia.
    Aikins ME; Sun X; Dobson H; Zhou X; Xu Y; Lei YL; Moon JJ
    J Control Release; 2024 Apr; 368():768-779. PubMed ID: 38492861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA damage-triggered activation of cGAS-STING pathway induces apoptosis in human keratinocyte HaCaT cells.
    Li C; Liu W; Wang F; Hayashi T; Mizuno K; Hattori S; Fujisaki H; Ikejima T
    Mol Immunol; 2021 Mar; 131():180-190. PubMed ID: 33423764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.